We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

LabMedica

Download Mobile App
Recent News Expo Clinical Chem. Molecular Diagnostics Hematology Immunology Microbiology Pathology Technology Industry Focus

World's First AI-Powered Solution for Gastric Cancer Detection

By LabMedica International staff writers
Posted on 17 Jun 2022
Print article
Image: Galen Gastric assists pathologists in improving gastric cancer detection (Photo courtesy of Ibex Medical)
Image: Galen Gastric assists pathologists in improving gastric cancer detection (Photo courtesy of Ibex Medical)

Gastric cancer is a prominent malignant disease in both men and women worldwide, with over a million new cases every year and a relatively poor prognosis. Pathologists play a crucial role in the detection and diagnosis of gastric cancer, with their assessments being vital for reaching correct treatment decisions by oncologists and improving patient survival rates. Over the last several years there has been an increase in overall cancer incidence, and rapid advances in personalized medicine have resulted in increases in the complexity of cancer diagnosis. Coupled with a global decline in the number of pathologists, these trends have led to growing workloads imposed on pathology departments. Clearly, there is a growing need for automated solutions and decision-support tools that help pathologists detect cancer to the utmost accuracy more rapidly, while enabling comprehensive and affordable quality control. Now, a first-of-its-kind artificial intelligence (AI)-powered solution supports pathologists in the detection of various types of gastric cancer.

Galen Gastric from Ibex Medical Analytics (Tel Aviv, Israel) is the world's first AI-powered solution for gastric cancer detection. Galen Gastric is an integrated diagnostics solution that supports pathologists in the detection of gastric cancer, H. pylori and other important clinical findings and in enabling shorter turnaround times and optimized diagnostic workflows. The solution was developed by a team of pathologists, data scientists and software engineers who implemented advanced deep learning technologies and trained algorithms on more than a million image samples, scanned from biopsy slides digitized using digital pathology.

The Galen Gastric solution has received CE mark follows pioneering results from a blinded, multi-site clinical study in which it demonstrated very high accuracy in detecting various types of gastric cancer, as well as Helicobacter pylori (H. pylori - a common gastric bacterial infection and a precursor for cancer), neuroendocrine lesions, dysplasia, adenoma and additional pathologies. These results validate the robustness of Galen Gastric and support its adoption by pathology institutes that aim to improve diagnostic quality and enhance productivity. Ibex is now partnering with laboratories, hospitals and health systems to implement AI for the diagnosis of gastric biopsies.

"Diagnosis of gastric biopsies remains a challenging task for pathologists. Gastric cancers are relatively scarce, often minute and sometimes easy to miss," said Judith Sandbank, MD, the principal investigator in the study. "We were impressed with the successful outcomes and the very high accuracy demonstrated by Galen Gastric in detection of different cancer types. It's also encouraging to see an AI solution that goes beyond cancer detection to accurately identify H. pylori, and provide additional insights on dysplasia, lymphoma, gastritis and other pathologies."

"We are proud to obtain this first-of-its-kind CE mark for AI-powered GI diagnostics in pathology, following excellent performance in a multi-site clinical study," said Chaim Linhart, PhD, Co-founder and CTO at Ibex Medical Analytics. "We trained the Deep Learning models of Galen Gastric on more than a million image samples from multiple labs to ensure it can accurately detect not only cancer but also a multitude of other clinically relevant features that impact future treatment for patients. Ibex now offers an unprecedented breadth of clinical applications, and this approval will enable our growing customer base to expand the usage of AI technology and provide pathologists with new insights as they review gastric biopsies, improving the quality of cancer diagnosis and care."

Related Links:
Ibex Medical Analytics 

New
Platinum Member
Flu SARS-CoV-2 Combo Test
OSOM® Flu SARS-CoV-2 Combo Test
Magnetic Bead Separation Modules
MAG and HEATMAG
Complement 3 (C3) Test
GPP-100 C3 Kit
New
Gold Member
Fully Automated Cell Density/Viability Analyzer
BioProfile FAST CDV

Print article

Channels

Clinical Chemistry

view channel
Image: The new ADLM guidance will help healthcare professionals navigate respiratory virus testing in a post-COVID world (Photo courtesy of 123RF)

New ADLM Guidance Provides Expert Recommendations on Clinical Testing For Respiratory Viral Infections

Respiratory tract infections, predominantly caused by viral pathogens, are a common reason for healthcare visits. Accurate and swift diagnosis of these infections is essential for optimal patient management.... Read more

Molecular Diagnostics

view channel
Image: The HelioLiver Dx test has met the coprimary and secondary study endpoints in the CLiMB trial (Photo courtesy of Helio Genomics)

Blood-Based Test Outperforms Ultrasound in Early Liver Cancer Detection

Patients with liver cirrhosis and chronic hepatitis B are at a higher risk for developing hepatocellular carcinoma (HCC), the most prevalent type of liver cancer. The American Association for the Study... Read more

Hematology

view channel
Image: The CAPILLARYS 3 DBS devices have received U.S. FDA 510(k) clearance (Photo courtesy of Sebia)

Next Generation Instrument Screens for Hemoglobin Disorders in Newborns

Hemoglobinopathies, the most widespread inherited conditions globally, affect about 7% of the population as carriers, with 2.7% of newborns being born with these conditions. The spectrum of clinical manifestations... Read more

Microbiology

view channel
Image: The POC PCR test shortens time for STI test results (Photo courtesy of Visby Medical)

POC STI Test Shortens Time from ED Arrival to Test Results

In a 2024 sexually transmitted infections (STIs) surveillance report by the World Health Organization (WHO), over 2.5 million cases were recorded, alongside a rise in the inappropriate use of antibiotics... Read more

Industry

view channel
Image: For 46 years, Roche and Hitachi have collaborated to deliver innovative diagnostic solutions (Photo courtesy of Roche)

Roche and Hitachi High-Tech Extend 46-Year Partnership for Breakthroughs in Diagnostic Testing

Roche (Basel, Switzerland) and Hitachi High-Tech (Tokyo, Japan) have renewed their collaboration agreement, committing to a further 10 years of partnership. This extension brings together their long-standing... Read more
LGC Clinical Diagnostics